Ikena Oncology (IKNA) News Today $1.55 -0.06 (-3.73%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest UpdateIkena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) saw a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 90,600 shares, an increase of 9.7% from the November 15th total of 82,600 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average trading volume of 58,300 shares, the days-to-cover ratio is currently 1.6 days.December 15, 2024 | marketbeat.comHC Wainwright Forecasts Higher Earnings for Ikena OncologyIkena Oncology, Inc. (NASDAQ:IKNA - Free Report) - Investment analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Ikena Oncology in a research note issued on Monday, November 11th. HC Wainwright analyst A. Maldonado now forecasts that the company will posNovember 14, 2024 | marketbeat.comBuy Rating for Ikena Oncology Driven by Promising IK-595 DevelopmentsNovember 11, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Ikena Oncology (NASDAQ:IKNA)HC Wainwright reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Ikena Oncology in a research report on Monday.November 11, 2024 | marketbeat.comIkena Oncology Reports Strategic Realignment and Financial PerformanceNovember 8, 2024 | markets.businessinsider.comIkena Oncology Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | globenewswire.comRenaissance Technologies LLC Sells 300,200 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA)Renaissance Technologies LLC cut its stake in Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 38.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 476,400 shares of the company's stock after sellinOctober 8, 2024 | marketbeat.comIkena Oncology (NASDAQ:IKNA) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comIkena Oncology, Inc. (NASDAQ:IKNA) Sees Large Drop in Short InterestIkena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) saw a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling 313,600 shares, a decrease of 10.8% from the July 31st total of 351,500 shares. Based on an average daily volume of 279,400 shares, the short-interest ratio is currently 1.1 days. Approximately 1.1% of the company's stock are sold short.September 1, 2024 | marketbeat.comIkena Oncology, Inc. (NASDAQ:IKNA) Sees Significant Decrease in Short InterestIkena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) saw a significant decrease in short interest in July. As of July 31st, there was short interest totalling 351,500 shares, a decrease of 10.7% from the July 15th total of 393,700 shares. Currently, 1.5% of the shares of the company are sold short. Based on an average daily volume of 295,600 shares, the days-to-cover ratio is presently 1.2 days.August 18, 2024 | marketbeat.comIkena Oncology, Inc. (NASDAQ:IKNA) Expected to Post Q3 2024 Earnings of ($0.26) Per ShareIkena Oncology, Inc. (NASDAQ:IKNA - Free Report) - Stock analysts at HC Wainwright lifted their Q3 2024 earnings estimates for shares of Ikena Oncology in a research report issued to clients and investors on Monday, August 12th. HC Wainwright analyst A. Maldonado now expects that the company willAugust 15, 2024 | marketbeat.comIkena Oncology, Inc.: Ikena Oncology Reports Second Quarter 2024 Financial ResultsAugust 10, 2024 | finanznachrichten.deIkena Oncology Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comJacobs Levy Equity Management Inc. Increases Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA)Jacobs Levy Equity Management Inc. raised its holdings in shares of Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 813.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 513,440 shares oAugust 3, 2024 | marketbeat.comIkena Oncology, Inc. (NASDAQ:IKNA) Sees Significant Decline in Short InterestIkena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 393,700 shares, a decrease of 70.2% from the June 30th total of 1,320,000 shares. Based on an average daily trading volume, of 318,100 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.7% of the company's stock are short sold.July 26, 2024 | marketbeat.comShort Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Decreases By 9.0%Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the recipient of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totalling 1,410,000 shares, a decrease of 9.0% from the May 31st total of 1,550,000 shares. Approximately 6.0% of the company's stock are short sold. Based on an average daily volume of 306,200 shares, the short-interest ratio is currently 4.6 days.July 3, 2024 | marketbeat.comIkena Oncology, Inc. (NASDAQ:IKNA) Sees Significant Growth in Short InterestIkena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the target of a significant increase in short interest in May. As of May 31st, there was short interest totalling 1,550,000 shares, an increase of 12.3% from the May 15th total of 1,380,000 shares. Based on an average trading volume of 337,100 shares, the short-interest ratio is presently 4.6 days. Currently, 6.6% of the company's stock are short sold.June 17, 2024 | marketbeat.comIkena Oncology, Inc. (NASDAQ:IKNA) Shares Bought by BVF Inc. ILBVF Inc. IL raised its stake in Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 50.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,769,164 shares of the company's stock after acquiring an additionalJune 13, 2024 | marketbeat.comIkena Oncology, Inc. (NASDAQ:IKNA) to Post Q2 2024 Earnings of ($0.27) Per Share, William Blair ForecastsIkena Oncology, Inc. (NASDAQ:IKNA - Free Report) - Equities researchers at William Blair lowered their Q2 2024 earnings per share estimates for Ikena Oncology in a research report issued on Wednesday, May 29th. William Blair analyst M. Phipps now forecasts that the company will earn ($0.27) per sJune 3, 2024 | marketbeat.comWedbush downgrades Ikena, cites discontinuation of lead assetMay 29, 2024 | msn.comIkena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing'May 29, 2024 | msn.comThis American Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For WednesdayMay 29, 2024 | msn.comHC Wainwright Cuts Ikena Oncology (NASDAQ:IKNA) Price Target to $4.00HC Wainwright decreased their target price on shares of Ikena Oncology from $11.00 to $4.00 and set a "buy" rating for the company in a research report on Wednesday.May 29, 2024 | marketbeat.comIkena Oncology (NASDAQ:IKNA) Downgraded by WedbushWedbush downgraded shares of Ikena Oncology from an "outperform" rating to a "neutral" rating and lowered their price objective for the company from $8.00 to $2.00 in a research report on Wednesday.May 29, 2024 | marketbeat.comIkena Oncology to Cut Half of Workforce, Discontinue Development of CandidateMay 28, 2024 | marketwatch.comIkena to cut workforce by 53%, explore strategic optionsMay 28, 2024 | msn.comUPDATE – Ikena Oncology Announces Strategic UpdateMay 28, 2024 | globenewswire.comIkena Oncology Announces Strategic UpdateMay 28, 2024 | globenewswire.comShort Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Rises By 9.4%Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 1,520,000 shares, a growth of 9.4% from the April 15th total of 1,390,000 shares. Based on an average daily volume of 388,400 shares, the short-interest ratio is currently 3.9 days. Approximately 6.0% of the company's stock are sold short.May 17, 2024 | marketbeat.comIkena Oncology, Inc. (NASDAQ:IKNA) Forecasted to Earn Q2 2024 Earnings of ($0.26) Per ShareIkena Oncology, Inc. (NASDAQ:IKNA - Free Report) - Wedbush raised their Q2 2024 EPS estimates for Ikena Oncology in a report released on Monday, May 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.26) per share for the quarter, up from their previousMay 16, 2024 | marketbeat.comIkena Oncology (NASDAQ:IKNA) Given Outperform Rating at WedbushWedbush reissued an "outperform" rating and set a $8.00 price objective on shares of Ikena Oncology in a research report on Tuesday.May 14, 2024 | marketbeat.comIKNA Stock Earnings: Ikena Oncology Beats EPS for Q1 2024May 13, 2024 | investorplace.comIkena Oncology Reports First Quarter 2024 Financial Results and Corporate UpdateMay 13, 2024 | globenewswire.comIkena Oncology, Inc. (NASDAQ:IKNA) Short Interest Up 11.2% in AprilIkena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,390,000 shares, an increase of 11.2% from the March 31st total of 1,250,000 shares. Approximately 5.5% of the shares of the stock are sold short. Based on an average trading volume of 424,100 shares, the short-interest ratio is currently 3.3 days.May 1, 2024 | marketbeat.comIkena Oncology, Inc. (IKNA)April 21, 2024 | finance.yahoo.comIkena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology ForumApril 10, 2024 | globenewswire.comIkena Oncology, Inc. (NASDAQ:IKNA) Sees Large Growth in Short InterestIkena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 1,120,000 shares, a growth of 15.0% from the February 29th total of 974,000 shares. Approximately 4.5% of the company's shares are sold short. Based on an average daily trading volume, of 388,000 shares, the days-to-cover ratio is currently 2.9 days.April 2, 2024 | marketbeat.comThe Analyst Landscape: 4 Takes On Ikena OncologyMarch 19, 2024 | markets.businessinsider.comIkena Oncology (NASDAQ:IKNA) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $11.00 price target on shares of Ikena Oncology in a research note on Tuesday.March 19, 2024 | marketbeat.comShort Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Rises By 47.0%Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 29th, there was short interest totalling 974,000 shares, a growth of 47.0% from the February 14th total of 662,400 shares. Approximately 3.9% of the company's stock are short sold. Based on an average daily volume of 349,300 shares, the days-to-cover ratio is currently 2.8 days.March 16, 2024 | marketbeat.comIkena Oncology Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 14, 2024 | finance.yahoo.comIkena Oncology, Inc. (NASDAQ:IKNA) Expected to Post FY2028 Earnings of ($0.36) Per ShareIkena Oncology, Inc. (NASDAQ:IKNA - Free Report) - Stock analysts at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for shares of Ikena Oncology in a research report issued on Tuesday, March 12th. HC Wainwright analyst A. Maldonado forecasts that the company will post earninMarch 14, 2024 | marketbeat.comIkena Oncology’s Promising Drug Pipeline Merits a Buy RatingMarch 13, 2024 | markets.businessinsider.comIkena Oncology: Q4 Earnings InsightsMarch 12, 2024 | benzinga.comWedbush Reaffirms Outperform Rating for Ikena Oncology (NASDAQ:IKNA)Wedbush reaffirmed an "outperform" rating and set a $8.00 target price on shares of Ikena Oncology in a research report on Tuesday.March 12, 2024 | marketbeat.comIkena Oncology, Inc.: Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | finanznachrichten.deIkena Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | globenewswire.comIkena Oncology to Participate in TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | globenewswire.comIkena Oncology Appoints Caroline Germa, M.D. as Chief Medical OfficerFebruary 21, 2024 | finance.yahoo.comIkena Oncology Appoints Caroline Germa, M.D. as Chief Medical OfficerFebruary 21, 2024 | globenewswire.com Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. IKNA Media Mentions By Week IKNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IKNA News Sentiment▼1.930.60▲Average Medical News Sentiment IKNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IKNA Articles This Week▼11▲IKNA Articles Average Week Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VALN News Today LRMR News Today FHTX News Today CCCC News Today IMMP News Today FDMT News Today CMPS News Today BNTC News Today ACIU News Today AMLX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IKNA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.